SCHEMBL5657887

SCHEMBL5657887

NC(=O)C1CC(N2CCNCC2)CCN1C(=O)[CH]Cc1ccc2[nH]ncc2c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.35
CALCRL Q16602 4/20 0.35
DRD4 P21917 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
MAPK1 P28482 1/20 0.34
ROCK2 O75116 7/20 0.34
GRIN2B Q13224 3/20 0.34
ROCK1 Q13464 2/20 0.34
CYP2D6 P10635 2/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
NEK2 P51955 1/20 0.33
CTSC P53634 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CLK2 P49760 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
STK17A Q9UEE5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659610 0.97 CALCRL (0.36) CYP3A4CALCRLDRD4SIGMAR1ROCK2
SCHEMBL3602596 0.86 CYP2D6 (0.41) DRD4SIGMAR1MAPK1ROCK2GRIN2B
SCHEMBL5659889 0.86 PARP1 (0.40) CYP3A4CALCRLSIGMAR1SLC6A2SLC6A4
SCHEMBL5658670 0.85 CALCRL (0.35) CYP3A4CALCRL
SCHEMBL5659937 0.85 CALCA (0.32)
SCHEMBL5658564 0.84 SLC6A2 (0.36) CYP3A4CALCRLDRD4SIGMAR1MAPK1
SCHEMBL5656765 0.84
SCHEMBL5660903 0.83 ROCK2 (0.36) CYP3A4CALCRLDRD4SIGMAR1ROCK2
SCHEMBL3601463 0.80 CALCRL (0.51) CYP3A4CALCRL
SCHEMBL5661183 0.77 ACACB (0.42) CYP3A4CALCRLROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US claimed
US-7205294-B2 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-17 US disclosed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BDKRB1, BDKRB2, CALCRL CYP3A4 1053/4885CALCRL 3/4885DRD4 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.